Enbrel (etanercept) / Pfizer, Amgen - LARVOL DELTA

Wogonin Mitigates Depression by Inhibiting TNF-α/TNFR1/CXCL1 Signalling-Mediated Astrocyte Activation. (PubMed, J Cell Mol Med) - "These effects of wogonin in vivo were reversed by co-administration of r-TNF-α and were replicated by treatment with the TNF-α inhibitor etanercept. These results demonstrate that wogonin may exert antidepressant effects by modulating the TNF-α/TNFR1/CXCL1 pathway, thereby improving neuroinflammation and astrocyte activation."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • CXCL1 • GFAP • TNFA • TNFRSF1A

The STARS trial: Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS (clinicaltrialsregister.eu) - P2/3 | N=260 | Recruiting | Sponsor: Giannina Gaslini Institute For Scientific Hospitalization And Care | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Arthritis • Immunology • Rheumatology

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (clinicaltrials.gov) - P2/3 | N=135 | Active, not recruiting | Sponsor: Sun Pharmaceutical Industries Limited | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2031 ➔ Aug 2031 | Trial primary completion date: Jul 2025 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Pediatrics • Psoriasis

Real-World Comparative Risk of Infections with Biologic Therapy in Pediatric Psoriasis: A Nationwide Cohort Study (AAD 2026) - "Methods This new-user cohort study used US claims data (December 2016-June 2023) to identify children aged 6 to 17 years with psoriasis and compared the risk of inpatient infections and outpatient infections requiring antimicrobial treatment in those initiating etanercept, ustekinumab, and interleukin -17 inhibitors (IL-17i: secukinumab or ixekizumab). Conclusions In this real-world cohort study among children with psoriasis treated with biologics, the risk of outpatient infections requiring treatment was similar between initiators of IL-17i, etanercept and ustekinumab. No serious inpatient infections were observed."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Infectious Disease • Pediatrics • Psoriasis

Efficacy of Biologics and Small Molecules for Pediatric Plaque Psoriasis: A Systematic Review of Randomized Control Trials (AAD 2026) - "Systemic therapies evaluated were apremilast (22.1%, 163/738), etanercept (19.9%, 147/738), secukinumab (16.5%, 122/738), ixekizumab (15.6%, 115/738), adalimumab (10.4%, 77/738), ustekinumab (9.9%, 73/738), and guselkumab (5.6%, 41/738). No treatment-related deaths were reported. Our results indicate that interleukin-17 inhibitors, particularly secukinumab and ixekizumab, achieve the highest efficacy in pediatric plaque psoriasis with favorable short-term safety profiles."

Clinical • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Psoriasis • IL17A

Early skin improvement, rather than treatment assignment, is associated with early nail improvement in moderate-severe nail psoriasis (AAD 2026) - "Ixekizumab 80 mg q2weeks is significantly superior to etanercept and placebo in causing skin and nail improvement in moderate-severe psoriasis patients. Skin improvement, not treatment assignment, is associated with nail improvement. Concomitant tobacco use impairs nail psoriasis improvement regardless of treatment."

Dermatology • Immunology • Psoriasis

Outbreak of Stevens-Johnson syndrome/Toxic epidermal necrolysis in Singapore secondary to illicit, off-label use of Armodafanil: A report of 5 cases (AAD 2026) - "Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are rare severe cutaneous adverse reactions that are traditionally caused by a few high notoriety drugs such allopurinol...In 2 patients who denied prior drug intake, toxicology analysis revealed urinary presence of Armodafinil & Modafinil...Ciclosporine (n=4) and Etanercept (n=1) was administered along with supportive care...Our reported 5 cases is likely a harbinger: Their popularity as a lifestyle biohack, property as a “less potent” drug of abuse, as well as their availability from unlicensed sources and online will likely fuel the increase. Lastly, toxicology studies are useful in elucidating causality in cases of SJS/TEN which may be otherwise classified as “idiopathic”."

Clinical • Narcolepsy • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Steven-Johnson Syndrome

Representation of Race and Ethnicity in Randomized Control Trials of Biologic Therapies for Psoriasis: A Scoping Review (AAD 2026) - " Following Joanna Briggs Institute methodology, we searched MEDLINE (PubMed), Embase (Elsevier), and Cochrane Library in June 2024 for RCTs evaluating efficacy and/or safety of adalimumab, infliximab, etanercept, bimekizumab, ustekinumab, and guselkumab. Black and Hispanic patients remain underrepresented in psoriasis biologic RCTs despite higher disease burden, and demographic reporting is inconsistent, limiting generalizability. Trials documenting race/ethnicity appeared in higher impact, more frequently cited journals. Future biologic trials should prioritize diverse recruitment and standardized demographic reporting to strengthen equity and applicability of findings."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Evidence-Based Biologic Selection for Moderate-to-Severe Psoriasis in Patients with IBD and Heart Failure (AAD 2026) - "These comorbidity-specific algorithms provide practical guidance for biologic selection in psoriasis, advancing care for dual IBD-HF comorbidity, a comparatively understudied population."

Clinical • Cardiovascular • Congestive Heart Failure • Dermatology • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • IL17A • IL23A

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators (AAD 2026) - "The immunomodulatory agents assessed included Adalimumab, Infliximab, Ixekizumab, Secukinumab, Tildrakizumab, Certolizumab pegol, Risankizumab, Etanercept, Guselkumab, and Ustekinumab. Inhibition of this inflammation by immunomodulators could impede PsA progression. Physicians can consider Risankizumab, Guselkumab, and Ustekinumab as treatment options for PsO patients with PsA risk factors to mitigate disease progression and improve patients’ quality of life."

Clinical • Immunomodulating • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Evaluating Etanercept for the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (AAD 2026) - "In this single-center retrospective study, etanercept administration was not associated with improved outcomes. Larger randomized controlled trials are required to better define etanercept’s role in the management of SJS/TEN."

Steven-Johnson Syndrome

Etanercept and Topical Silver Nitrate in SJS and TEN. (AAD 2026) - No abstract available

Steven-Johnson Syndrome

F097 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies (AAD 2026) - "In the first part will be presented the efficacy and tolerance of etanercept associated with topical silver Nitrate in spray in SJS...Compare this treatment with other treatments for SJS/TEN 3. Differentiate between different management options in SJS and TEN."

Steven-Johnson Syndrome

Effects of sialylated oligosaccharides on the N- and O-glycosylation of etanercept in recombinant CHO cells. (PubMed, Appl Microbiol Biotechnol) - "• Among the sialylated oligosaccharides, disialyllacto-N-neotetraose (DSLNnT) increased intracellular CMP-SA the most in two rCHO cells. • The effect of sialylated oligosaccharides on sialylation was also evaluated in HEK293 cells; however, no significant enhancement was observed."

Journal

Coverage generosity of novel anti-rheumatic drugs in Medicare Advantage and stand-alone Part D plans. (PubMed, Arthritis Rheumatol) - "The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted."

Journal • Medicare • Reimbursement • US reimbursement • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Computational modeling-directed combination treatment with etanercept and mifepristone mitigates neuroinflammation in a mouse model of Gulf War Illness. (PubMed, PLoS One) - "Supporting results from the computational modeling of this treatment, we found that this drug combination significantly alleviates the underlying neuroinflammation associated with Gulf War Illness. The fusion of computational and in vivo preclinical treatment evaluation may provide a highly useful and translationally relevant means by which to identify successful treatment paradigms for Gulf War Illness."

Journal • Preclinical • Inflammation

Five-Year Treat-to-Target Outcomes in Early RA: Impact of a Temporary 6-Month Etanercept Course Based on Initial COBRA-Slim Response in the CareRA2020 Trial (EULAR 2026) - No abstract available

Improving remission rates in early rheumatoid arthritis: Targeting predicted poor methotrexate responders, based on naïve CD4+ T-cell frequency, with additional etanercept: the TEEMS trial, a pilot proof of concept study. (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD4

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. (PubMed, Ann Rheum Dis) - "These updated EULAR recommendations provide consensus on RA management based on currently available evidence regarding efficacy, safety, and cost."

Journal • Cardiovascular • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION POST–CAR-T THERAPY IN CHILDREN WITH PRE-B ACUTE LYMPHOBLASTIC LEUKAEMIA: NATIONAL POLISH EXPERIENCE (EBMT 2026) - "Conditioning regimens included total body irradiation with etoposide in nine patients; treosulfan, fludarabine, and thiotepa in two patients; and fludarabine with cyclophosphamide in one patient. Post-transplant complications included one patient developing severe veno-occlusive disease, treated with defibrotide. Four children developed acute skin graft-versus-host disease (GVHD): three responded to steroid therapy, while one had steroid-resistant GVHD requiring etanercept. One child experienced graft rejection and required a second HSCT.Two patients were treated with cidofovir for adenovirus reactivation, and one subsequently developed chronic bone marrow failure... Hematopoietic stem cell transplantation remains an important therapeutic strategy in selected patients following CAR-T therapy. The primary indication for HSCT in this setting is disease relapse; however, second CAR-T infusions are increasingly considered. Allogeneic HSCT after CAR-T is also recommended as..."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Transplant Rejection • Transplantation • CD34

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION POST–CAR-T THERAPY IN CHILDREN WITH PRE-B ACUTE LYMPHOBLASTIC LEUKAEMIA: NATIONAL POLISH EXPERIENCE (EBMT 2026) - "Conditioning regimens included total body irradiation with etoposide in nine patients; treosulfan, fludarabine, and thiotepa in two patients; and fludarabine with cyclophosphamide in one patient. Post-transplant complications included one patient developing severe veno-occlusive disease, treated with defibrotide. Four children developed acute skin graft-versus-host disease (GVHD): three responded to steroid therapy, while one had steroid-resistant GVHD requiring etanercept. One child experienced graft rejection and required a second HSCT.Two patients were treated with cidofovir for adenovirus reactivation, and one subsequently developed chronic bone marrow failure... Hematopoietic stem cell transplantation remains an important therapeutic strategy in selected patients following CAR-T therapy. The primary indication for HSCT in this setting is disease relapse; however, second CAR-T infusions are increasingly considered. Allogeneic HSCT after CAR-T is also recommended as..."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Transplant Rejection • Transplantation • CD34

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators. (PubMed, Proc (Bayl Univ Med Cent)) - "The immunomodulatory agents assessed included adalimumab, infliximab, ixekizumab, secukinumab, tildrakizumab, certolizumab pegol, risankizumab, etanercept, guselkumab, and ustekinumab. Overall, IL-23 inhibitors risankizumab, guselkumab, and ustekinumab had the greatest decreased risk of PsA. Physicians can consider risankizumab, guselkumab, and ustekinumab as treatment options for psoriasis patients with PsA risk factors to mitigate disease progression and improve patients' quality of life."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Systemic Treatments for Pediatric Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Living Systematic Review (AAD 2026) - "Tumor necrosis factor-alpha inhibitors, particularly etanercept, showed potential... The current evidence supports steroid monotherapy and supportive care as effective options for pediatric SJS/TEN. These findings may inform clinical decision-making and guide therapeutic strategies for this vulnerable population."

Clinical • Review • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology • Pediatrics • Steven-Johnson Syndrome

High Reporting Odds of Alopecia Among Biologics: Insights from the FDA Adverse Events Reporting System (FAERS) Database from 2018–2024 (AAD 2026) - "Notably, adalimumab, etanercept, infliximab, dupilumab, secukinumab, ustekinumab, and rituximab were found to be associated with increased odds of reporting alopecia, whereas guselkumab was associated with lower reporting odds of alopecia compared to the remainder of the FAERS (p<0.0001). While these data do not establish causality, they may help guide clinicians in treatment decisions, particularly for patients whose concerns about alopecia could impact medication adherence. These findings should be interpreted in the context of FAERS as a spontaneous self-report database, with the potential for concomitant medication use, data duplication, or underreporting."

Adverse events • Alopecia • Immunology • Inflammation • CD20 • CD4 • IL23A